News · 26 weeks760%
2026-03-012026-08-23
Mix4390d
- Insider30(70%)
- Other7(16%)
- SEC Filings3(7%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 101,502 units (SEC Form 4) (withholding obligation)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP, Chief Financal Officer Sylvain Jereme M covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.96% to 150,390 units (SEC Form 4) (withholding tax)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERPresident, CEO, and Director Leach Jacob Steven covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 0.35% to 418,908 units (SEC Form 4) to satisfy withholding tax4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP Chief People & Culture Off Stern Sadie covered exercise/tax liability with 1,451 shares, decreasing direct ownership by 1% to 128,608 units (SEC Form 4) (withholding tax)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERExecutive Chair Sayer Kevin R sold $2,408,242 worth of shares (26,756 units at $90.01) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 302,214 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon sold $156,281 worth of shares (1,700 units at $91.93) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 102,953 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Augustinos Nicholas gifted 1,075 shares (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Heller Bridgette P sold $89,349 worth of shares (1,012 units at $88.29) as part of a pre-agreed trading plan, decreasing direct ownership by 3% to 29,570 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Foletta Mark G sold $330,640 worth of shares (4,000 units at $82.66) as part of a pre-agreed trading plan (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- SECSEC Form 10-Q filed by DexCom Inc.10-Q - DEXCOM INC (0001093557) (Filer)
- SECDexCom Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - DEXCOM INC (0001093557) (Filer)
- PRDexcom Reports Second Quarter 2026 Financial ResultsDexCom, Inc. (NASDAQ:DXCM) today reported its financial results as of and for the quarter ended June 30, 2026. Second Quarter 2026 Financial Highlights: Revenue grew 13% year-over-year to $1.308 billion on a reported basis and 12% year-over-year on an organic1 basis. U.S. revenue grew 11% and international revenue grew 19% on a reported basis and 16% on an organic1 basis, all on a year-over-year basis. GAAP operating income of $318.3 million or 24.3% of revenue, an increase of 590 basis points compared to the second quarter of 2025. Non-GAAP operating income* of $328.3 million or 25.1% of reported revenue, an increase of 590 basis points compared to the second quarter of 2025.
- PRDexcom Announced as First Participant Selected for FDA's TEMPO Digital Health Devices Pilot ProgramParticipation advances the company’s vision and regulatory pathway for earlier intervention, screening for prediabetes and Type 2 diabetes and empowerment Dexcom (NASDAQ:DXCM), the global leader in glucose biosensing, today announced it is the first company selected by the U.S. Food and Drug Administration (FDA) to participate in the Technology-Enabled Meaningful Patient Outcomes (TEMPO) Pilot Program, a first-of-its-kind initiative designed to evaluate innovative digital health technologies that improve chronic disease management while generating real-world evidence. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260722426337
- INSIDERExecutive Chair Sayer Kevin R sold $2,041,999 worth of shares (26,756 units at $76.32) as part of a pre-agreed trading plan, decreasing direct ownership by 8% to 328,970 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon sold $126,514 worth of shares (1,700 units at $74.42) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 104,653 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom G7 15 Day Receives Health Canada Authorization: Extending Wear and Continuity for Canadian Adults Living with DiabetesDexcom G7 15 Day is the longest‑lasting and most accurate1-4 CGM system authorized by Health Canada, providing real-time glucose readings for an industry-leading 15.5 days5. Dexcom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, announced today that Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System (CGM) for people 18 years and older living with diabetes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713940133/en/Dexcom G7 15 Day receives Health Canada authorization. Compatible smart devices sold separately. For a list of compatible devices, see dexcom.com/compatibility. D
- PRDexcom Schedules Second Quarter 2026 Earnings Release and Conference Call for July 30, 2026 at 4:30 p.m. Eastern TimeDexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its second quarter 2026 financial results after market close on Thursday, July 30, 2026. Management will hold a conference call to review the company's second quarter 2026 performance starting at 4:30 p.m. (Eastern Time) on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the Dexcom investor relations website at investors.dexcom.com and will be archived there for future reference.To listen to the conference call, please dial (888) 414-4585 (US/Canada) or (646) 960-0331 (International) and use the confirmation ID "9430114" approximately five minutes prior to the star
- INSIDERExecutive Chair Sayer Kevin R sold $1,926,432 worth of shares (26,756 units at $72.00) as part of a pre-agreed trading plan, decreasing direct ownership by 7% to 355,726 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom Further Advances Vision of Glucose Biosensing for AllAt Aspen Ideas: Health, Dexcom announced regulatory milestones, including pediatric clearance for Stelo, further advancing access to glucose biosensing in the United States.The company also announced details regarding the rollout of its fully reimagined Stelo app experience launching in July in the US, helping make glucose insights more approachable and actionable for people seeking better health.Expanded international availability of Stelo is also planned for the United Kingdom, Australia, New Zealand and South Korea starting later this year and will continue into 2027.DexCom, Inc. (NASDAQ:DXCM), the global leader in glucose biosensing, today announced at Aspen Ideas: Health a series of mil
- ANALYSTDeutsche Bank initiated coverage on Dexcom with a new price targetDeutsche Bank initiated coverage of Dexcom with a rating of Buy and set a new price target of $86.00
- INSIDEREVP Chief Legal Compliance Off Brown Michael Jon sold $128,435 worth of shares (1,700 units at $75.55) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 106,353 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- INSIDERDirector Foletta Mark G sold $296,540 worth of shares (4,000 units at $74.13) as part of a pre-agreed trading plan (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using InsulinDexcom sponsored CONNECT randomized controlled trial expected to help establish new standard of care for CGM use by people with Type 2 diabetes not using insulin around the world. Showed use of Dexcom G7 led to clinically and statistically significant reduction in HbA1c and improvement in quality of glucose control, including time in range and level 1 and 2 hyperglycemia.1 Demonstrated additional clinically significant improvement in A1C reduction across study participants using Dexcom G7 in combination with various diabetes medications, including metformin, GLP-1s and SGLT2s.1 DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonst
- INSIDEREVP, Chief Commercial Officer Coleman Jon sold $722,628 worth of shares (9,823 units at $73.56) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 95,450 units (SEC Form 4)4 - DEXCOM INC (0001093557) (Issuer)
- PRDexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026Highly anticipated presentation of results from the CONNECT randomized control trial will be presented during the ADA Scientific Sessions conference on Saturday, June 6 at 1:45 p.m. CDT. Early access launch of a completely reimagined Stelo app will define a new era of glucose tracking for all people not on insulin seeking better health. Acquisition of Nutrisense will strengthen Dexcom's ability to provide personalized nutrition education and coaching to improve diabetes management and help further establish CGM as an effective tool for preventative care. DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforci
DXCM FAQ
7 questionsWhat does DexCom Inc. do?
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop...Where does DXCM stock trade?
DexCom Inc. (DXCM) is listed on NASDAQ.What sector and industry is DXCM in?
DexCom Inc. operates in the Health Care sector, Medical/Dental Instruments industry.When did DexCom Inc. go public?
DexCom Inc. (DXCM) completed its IPO in 2005.What are analysts saying about DXCM?
DexCom Inc. has had 8 recent analyst actions on file. The most recent action was from Deutsche Bank: Buy on 2026-06-23.What companies are similar to DXCM?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), BDX (Becton Dickinson and Company), MDLN (Medline Inc.). Compare DXCM side-by-side with any of them on Quantisnow.How can I track DXCM on Quantisnow?
Quantisnow aggregates DexCom Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DXCM to receive live email and push alerts on every new disclosure.